^
Evidence Level:
Sensitive: A1 - Approval

[IDH2 mutation-Acute Myelogenous Leukemia-enasidenib]

Source:
Excerpt:
IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDAapproved test